Lactic Acidosis Associated with Stavudine Administration: A Report of Five Cases

Citations Over TimeTop 10% of 2000 papers

Abstract

Type "B" lactic acidosis has been described in patients receiving the nucleoside analogs zidovudine, didanosine, and fialuridine. Lactic acidosis has also been described in 4 patients receiving combination therapy with stavudine and lamivudine. We describe the development of chronic type "B" lactic acidosis in 3 patients receiving stavudine as a single agent and in 2 patients receiving combination therapy with stavudine and either lamivudine or delavirdine, a nonnucleoside analog. All patients presented with abdominal pain, vomiting, and hepatic steatosis. Other signs of mitochondrial toxicity included pancreatitis and myopathy (2 cases). The mean duration of stavudine therapy was 9.4 months, and the mean observed peak lactate level+/-SD was 10.3+/-5 mmol/L. After discontinuation of stavudine treatment, lactic acidosis improved in 4 patients after 4-60 weeks, and 1 patient died. Evaluations for other causes of lactic acidosis, including hypoxemia, malignancy, sepsis, and cardiogenic shock, were negative.

Related Papers

• → The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study(2008)48 cited
• → Nucleoside Reverse Transcriptase Inhibitor Usage and the Incidence of Peripheral Neuropathy in HIV/AIDS Patients(2003)40 cited
• → Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature(2003)9 cited
• → Effect of temperature on the high-performance liquid chromatographic separation of the anti-HIV agents, didanosine and stavudine(1996)1 cited
• → Effect of temperature on the high‐performance liquid chromatographic separation of the anti-HIV agents, didanosine and stavudine(1996)